




American Society of Hematology

Helping hematologists conquer blood diseases worldwide



# ASH's Strategy to Address DEI in Hematology Clinical Trials

Alice Kuaban, MS  
American Society of Hematology

# The Challenge

- Ensuring hematology clinical trials reflect the epidemiology of the disease and are inclusive of the population to benefit from the therapeutic under investigation.
- Initial focus on classical hematologic diseases
  - Small numbers of patients (<100)
  - Recruitment can be difficult
  - Novel trial designs are needed to generate meaningful results



# Why is this important?

## Having diverse clinical trials:

- Builds trust in medical research and institutions
- Promotes fairness for potential participants and their communities
- Ensures that study findings can be generalizable\*
- Advances biomedical knowledge and drives scientific innovation



# ASH's Strong Commitment to DEI




“The American Society of Hematology is committed to addressing and reversing historic inequities in hematology, supporting scientists and clinicians from backgrounds underrepresented in medicine, and elevating diverse voices across our patient and healthcare communities. ASH’s efforts in diversity, equity and inclusion apply to everyone, regardless of race, ethnicity, religion, age, sexual orientation, gender identity or expression, ability, national origin or other attributes.”




# How is ASH Addressing this Challenge?

The ASH  
Roadmap to  
Integrate DEI in  
Clinical Trials



# Representation in the Roadmap Initiative



# Headlines from the Initiative



Lived Experience Experts (LEEs)

Lived Experience Experts involved **throughout the clinical trial life cycle** (design, implementation, dissemination).



Community Physicians


Community physicians need to be **engaged** in the clinical trial ecosystem and their contributions need to be **acknowledged**.



DEI at each step

**Sponsors need guidance** on how to incorporate DEI principles throughout the trial life cycle.

# Headlines from the Initiative



## Inclusion/Exclusion Criteria

For rare disease, determinations about trial inclusion/exclusion criteria must be **evaluated early** to determine implications on **diversity, accessibility, and alignment with real-world results.**



## Decentralized Clinical Trials

Decentralized Clinical Trial options can enhance access.





# Headlines from the Initiative



## Institutional Review Boards

IRBs have a role to play in enhancing diversity in clinical trials.



## Global Standardization

Global definitions regarding diversity and inclusivity in clinical research are needed.



# ASH is Now Taking Steps To Address All The Key Headlines from the Roadmap Initiative



# Developing DEI Focused Resources for the Hematology Trialist - Toolkit




## (NEW!) ASH DEI TOOLKIT FOR CLINICAL TRIAL SPONSORS

This guide is designed to help trial sponsors incorporate DEI principles throughout the trial life cycle.

### ACTIONABLE STEPS TO INCORPORATE DEI IN THE CLINICAL TRIAL PROCESS



# Exploring the Creation of a Learning Ecosystem Focused on Building Inclusive Trials



✨ Your expertise matters in shaping the future of clinical trials. Take a brief survey to share your journey and insights on promoting diversity and inclusivity in research. Together, let's make a difference! [Take the survey>>](#)



# Creating Educational Resources on DEI & Clinical Trials



**Submission of  
Manuscripts to Blood**



**Annual Meeting  
Content**



# Integrating DEI into Study Design at the ASH Clinical Research Training Institute

1. CRTI is a unique year-long education and mentoring program
2. Focused on the foundation, methodologies, and application of patient-oriented clinical research
3. Geared towards hematology fellows and junior faculty at academic medical centers
4. **Incorporating DEI principles as new addition to the curriculum**
5. **Goal: To produce leaders armed with ideas for clinical hematology research and the tools and resources to make their ideas a reality**



# Request for Demographic Information in Clinical Trial Studies Submitted to ASH

- Demographic Information (sex, gender, race, ethnicity, age, disability, or other relevant factors of enrolled subjects) will be requested of individuals submitting and/or presenting on clinical studies:
  - **ASH Events** (including relevant Annual Meeting invited program sessions, submitted abstracts, and oral and poster presentations; small scientific and educational meetings).
  - **ASH Publications**
- If demographics are not available, the investigator will be asked to describe the limitations that prevented these data from being collected.



# Questions

